ALTEOGEN Inc. (196170) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for ALTEOGEN Inc. (196170:KRX), powered by AI.
- Current Price
- ₩349,000
- P/E Ratio
- 132.0
- Market Cap
- 18.7T
- Sector
- Healthcare
What is the ALTEOGEN Inc. stock price forecast?
ALTEOGEN Inc. is currently trading at ₩349,000. View real-time AI analysis on Alpha Lenz.
What is ALTEOGEN Inc. insider trading activity?
View the latest insider trading data for ALTEOGEN Inc. on Alpha Lenz.
What is ALTEOGEN Inc.'s P/E ratio?
ALTEOGEN Inc.'s P/E ratio is 132.0.
ALTEOGEN Inc.
KRX · 196170“ALTEOGEN Inc. trades at a P/E of 132.0 (premium valuation) with strong ROE of 39.4%. 3Y revenue CAGR of 95.7% highlights clear growth momentum.”
Ask for details →Company Overview
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; and Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“ALTEOGEN Inc. trades at a P/E of 132.0 (premium valuation) with strong ROE of 39.4%. 3Y revenue CAGR of 95.7% highlights clear growth momentum.”
Ask for details →Frequently Asked Questions
ALTEOGEN Inc. (ticker: 196170) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 155 employees. Market cap is $18.7T.
The current price is ₩349,000 with a P/E ratio of 132.01x and P/B of 42.01x.
ROE is 39.42% and operating margin is 49.52%. Annual revenue is $215.9B.